Handsome Dividend of Rs. 80: Get Credit By March 7, Record Date On February 21; Should You Buy Today?

One of the largest VMS businesses in India, Procter & Gamble Health Limited produces and distributes vitamins, minerals, and supplements for a better quality of life and a healthier lifestyle. Products under this brand include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.

Procter & Gamble Health Dividend

"We are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2024-25 of Rs. 80 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before March 7, 2025. As informed earlier in our letter dated January 31, 2025, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 21, 2025," said Procter & Gamble Health in a stock exchange filing.

Procter & Gamble Health Financials

The company's revenues of Rs 304 crores were flat compared to Q3FY24. The quarter's Profit After Tax (PAT) was Rs 91 crores, which represents a 26 percent rise over the same period last year. The operating Profit After Tax (PAT) climbed 13% in Q3FY25.

Mr. Milind Thatte, Managing Director, P&G Health India, said, "This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike."

Procter & Gamble Health Share Price Target

Hardik Matalia - Derivative Analyst at Choice Broking said, "PGHL is currently trading at ₹5,301.80, exhibiting a sideways as it fluctuates within the ₹5,114-₹5,581 range since mid-January 2025, indicating a neutral market sentiment. The Relative Strength Index (RSI) stands at 48.74, reinforcing the stock's consolidation phase and suggesting that it may continue trading within this range until a decisive breakout occurs."

"However, PGHL is currently positioned above the 200-day Exponential Moving Average (EMA) and appears to be taking support at this level. A close above the 20-day and 50-day EMAs could provide a bullish signal, potentially indicating the beginning of an upward trend. If the stock approaches the key support level of ₹5,114 and breaches it, the next potential support lies around ₹5,000, which could present a buying opportunity if reversal signals emerge," the analyst added.

"On the other hand, if PGHL sustains above the critical resistance level of ₹5,581 and breaks out with strong momentum, it could indicate a bullish reversal, offering an attractive entry point for investors. Considering the current market conditions, a long position at ₹5,301 may be viable, with a target range of ₹5,600-₹5,700. To manage risk effectively, placing a stop-loss around ₹5,114 would be a prudent strategy to mitigate potential downside risks," Hardik Matalia further commented.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.